At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Lazertinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients With EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating Lazertinib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 29 participants across 9 sites in 3 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of Lazertinib when given orally to participants with epidermal growth factor receptor single activating mutation positive (EGFRm+) locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesSpain, United Kingdom, United States
CollaboratorsYuhan Corporation
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartOct 2019
Primary CompletionJan 2021
Study CompletionNov 2022
TodayJul 2026
First PostedAug 30, 2019
Enrollment StartOct 16, 2019
Primary CompletionJan 8, 2021
Study CompletionNov 14, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.8 years ago
Interventions
Lazertinibdrug
Participants will receive Lazertinib tablets once daily.